Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917456 | 0.83 | KMT2A (0.48) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4921076 | 0.83 | MAPT (0.60) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4908696 | 0.83 | NPC1 (0.52) | MAPTMEN1KMT2AALDH1A1DUSP3 | |
| SCHEMBL4916241 | 0.81 | DYRK1A (0.56) | DYRK1AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4918411 | 0.80 | LCK (0.46) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4911522 | 0.80 | MAPT (0.52) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4916206 | 0.79 | MAPT (0.48) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4916854 | 0.79 | LCK (0.54) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4915377 | 0.79 | MAPT (0.59) | DYRK1AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4922841 | 0.79 | CHRM4 (0.56) | MAPTTP53MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | claimed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | DYRK1A 839/4885MAPT 1314/4885TP53 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.